Ibogaine vs Psilocybin

Both are Schedule I, both are taken once or a few times rather than daily, and both attract the language of transformation. The evidence behind them is at different stages, and the ways they can hurt someone are almost unrelated.

Side by side

What “in phase 3” does and does not mean

Psilocybin is genuinely further along. Three phase 3 trials in depression have completed or are active: two in treatment-resistant depression, enrolling 258 and 572 people, and one in major depressive disorder enrolling 238.

None has published a result. All three registry entries show no results posted. The sponsor of the two largest has announced topline findings in press releases, and stated in February 2026 that it had not yet submitted a new drug application.

The effect shrank as the trials got better

This is the pattern worth carrying away, and it is visible across three sources.

The last two are sponsor-reported topline figures rather than published results.

The four are not strictly commensurable: the populations differ, the comparators differ, and so do the timepoints. Part of the decline is that. But the direction is consistent, and it runs the way effects usually run when a field moves from small trials to large ones. Separately, the largest independent trial using an active placebo missed its primary endpoint outright.

None of this means psilocybin does nothing. It means the early numbers were not the real numbers, which is exactly the trajectory ibogaine’s uncontrolled literature has never been forced through.

A 2026 analysis in JAMA Psychiatry put a sharper point on it. Comparing psychedelic therapy against open-label antidepressant treatment, so that both sides were equally unblinded, it found no significant difference. Blinding changed the apparent size of the antidepressant effect but not the psychedelic one, which the authors read as confirmation that psychedelic trials are effectively always open-label.

For addiction specifically, the gap narrows

Most psilocybin evidence is about depression. On addiction there are four randomised trials, and they do not all point the same way.

Alcohol. Ninety-five people randomised, ninety-three analysed. Heavy drinking days were 9.7 per cent on psilocybin against 23.6 per cent on the comparator, a difference of 13.9 percentage points. It is one trial, and the comparator was diphenhydramine, a weak active placebo against a full psilocybin dose. No phase 3 result exists; a French phase 3 is recruiting with completion estimated for 2030.

Alcohol again, and null. A Swiss trial randomised thirty-seven people who had just completed withdrawal treatment to a single 25 mg dose or placebo, with brief psychotherapy. It found no significant difference in abstinence duration at four weeks. It is smaller than the American trial and it asked a narrower question, relapse prevention rather than drinking reduction, and its result was negative.

Cocaine. A randomised trial in forty people published in 2026 reported urinalysis-confirmed abstinence favouring psilocybin through 180 days. It is the most recent and among the more rigorous, and it is one trial.

Smoking. Eighty-two people, biochemically verified abstinence at six months of 40.5 per cent on psilocybin against 10.0 per cent on nicotine patch. The comparator deserves noting: a nicotine patch is an approved treatment that works, which makes it a far more demanding benchmark than an inert placebo. A strong result, then, and the paper states plainly that participants and investigators were unblinded to condition. It is a pilot, single site, recruited over eight years, in psychiatrically healthy people.

Against that, ibogaine has no randomised trial reporting drug use at all. On addiction evidence psilocybin is ahead, and neither is where the marketing suggests.

The safety comparison is genuinely lopsided

This is the one place the two separate cleanly, and it is worth stating precisely rather than in either direction’s favour.

Psilocybin has no established cardiac risk analogous to ibogaine’s. Its documented acute cardiovascular effects are transient rises in blood pressure and heart rate.

The question has been asked directly, which is worth saying rather than implying it was ignored. A 2022 study tested psilocin against the same hERG channel ibogaine blocks and found no clinically relevant blockade. A dedicated cardiac-repolarisation trial in sixty people, measuring the QT interval after a supratherapeutic dose, completed in August 2023 and has never reported its results. So the reassurance is real but incomplete, and one relevant trial is sitting unpublished, which is a criticism this site makes of ibogaine’s sponsors too.

The residual cardiac concern for psilocybin is theoretical: a receptor it binds is implicated in valve fibrosis by other drugs, and the worry attaches to chronic repeated dosing rather than to a single supervised session. It has not been demonstrated in humans.

Ibogaine’s cardiac risk is measured, replicated and lethal. It blocks the hERG channel at concentrations people reach, half of a hospital cohort of fourteen exceeded a corrected QT of 500 milliseconds, and nineteen deaths outside West Central Africa are documented in the forensic literature between 1990 and 2008, with further cases reported since.

That asymmetry is real and it should not be softened.

Where psilocybin’s harms actually are

They are psychological, and they are not zero.

From the registry filing of one phase 2b trial, covering the twelve weeks after dosing:

All three serious suicidal-behaviour events occurred in the highest-dose arm. That is the sponsor’s own filing, not a critic’s reading, and the paper’s abstract states that suicidal ideation, behaviour or self-injury occurred in all dose groups. A 2026 trial separately reported one in-trial case of persistent perceptual disorder as a serious adverse reaction.

A systematic review of adverse events across 214 studies found serious adverse events in no healthy participants and in roughly 4 per cent of participants who had a pre-existing neuropsychiatric disorder. The same review notes that among the 68 studies published since 2005, fewer than a quarter described a systematic approach to assessing adverse events at all.

The legal picture differs in a way that matters

Both are Schedule I federally in the United States. But Oregon and Colorado have built state licensing schemes for supervised psilocybin services, which changes the practical position considerably: a person can access it domestically, in a licensed setting, without leaving the country.

Those schemes are not medical approval. Facilitators are not prescribers, no diagnosis is required, and nothing is being treated in the legal sense.

Elsewhere the position differs again. Australia has allowed authorised psychiatrists to prescribe psilocybin for specific diagnoses since 2023, and Canada and Switzerland grant individual authorisations through special-access routes. None of those is a marketing approval, and none exists for ibogaine anywhere.

Ibogaine has no equivalent open anywhere in the United States, which is why the treatment happens abroad. Colorado’s statute does name ibogaine among its natural medicines, so the two are not permanently separate on this point, but nothing has opened. Where ibogaine is legal maps that, and Colorado covers the statute.

Nobody has compared them

The only head-to-head study of psilocybin and ibogaine is a 2026 experiment in rats on cocaine-seeking, and its own title qualifies the finding as extinction enhancement without relapse prevention.

In humans, nothing. Anyone ranking the two is comparing separate literatures with different populations, endpoints and follow-up, which is what this whole page has done, with that caveat attached.